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In recent years, the negative impact of oxidative stress on fertility has become widely recognised. Several studies
have demonstrated its negative effect on the number and quality of retrieved oocytes and embryos following
in-vitro fertilisation (IVF). Melatonin, a pineal hormone that regulates circadian rhythms, has also been shown to
exhibit unique oxygen scavenging abilities. Some studies have suggested a role for melatonin in gamete biology.
Clinical studies also suggest that melatonin supplementation in IVF may lead to better pregnancy rates. Here we
present a critical review and summary of the current literature and provide suggestions for future well designed
clinical trials.
Keywords: Melatonin, Oxidative stress, Oxygen scavenger, Infertility, In-vitro fertilisationIntroduction
Over the last 35 years, infertility treatment has become
more acceptable and with improvements in technology
the pressure for improved success rates has mounted.
This trend is perpetuated by a perceived ability to delay
and yet successfully achieve pregnancy through assisted
reproductive technologies (ART) [1]. Technological ad-
vancement and societal expectations therefore mandate
continual improvement in in-vitro fertilisation (IVF) suc-
cess rates, inspiring research into novel adjuvant therapies
designed to improve IVF outcomes. More recently, it has
been discovered that an imbalance of reactive oxygen spe-
cies, or ‘oxidative stress’, can have a negative impact on
the success of infertility treatments, and furthermore, in-
vestigators have begun addressing potential mechanisms
of preventing these effects with the use of novel oxygen
scavengers such as melatonin. It may be that these agents
have a positive effect on pregnancy success rates following
IVF treatment. We present a summary of the most recent
work investigating melatonin and its affect on oxidative
stress, with a focus on the reproductive system and the
treatment of infertility.* Correspondence: shavif@hotmail.com
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Melatonin: synthesis and degradation
Melatonin (N-acetyl-5-methoxytryptamine) was first iso-
lated in 1958 as a neuro-hormone mainly synthesised and
secreted from the pineal gland [2]. Since its discovery, fur-
ther investigation has revealed that it is also produced by
several other organs. It has been found in the gastrointes-
tinal tract [3], brain [4], eye [5], lungs [6], skin [7], kidney
[8], liver [9], thyroid, thymus, pancreas [10], immune sys-
tem [11] and reproductive system [12]. Melatonin is an
indoleamine, which is synthesised from the essential amino
acid, tryptophan [13]. Its production is dependent on ambi-
ent illumination, with release being suppressed by light.
Hence, endogenous levels in plasma begin to increase be-
tween 1800 and 2000 hrs and peak between midnight and
0500 hrs with levels before 0900 hrs being five times higher
than those after 1100 hrs [14]. This diurnal variation can
make comparative studies challenging.
In an investigation of the pharmacokinetics of exogen-
ous orally administered melatonin, Waldhauser and asso-
ciates found that the increase in serum levels after oral
administration of melatonin is rapid (60–150 minutes), as
is its excretion [15]. It does not accumulate in the blood,
with repeat dosing simply resulting in peak levels being
maintained for longer [15]. Melatonin is hepatically meta-
bolised and renally excreted [16]. Hence, melatonin has a
short half-life and both melatonin and its metabolites can
be measured in serum, urine and saliva [17,18].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Classical actions
Melatonin has been identified as a key factor in the
regulation of circadian rhythms and the sleep-wake cycle
[18]. Long exposure to artificial lighting leads to a reduc-
tion in endogenous melatonin exposure [19]. Melatonin
is thus associated with sleep disturbances including in-
somnia, and much of the literature is focused in this area
[20-22]. It also appears to regulate reproductive seasonal
variation in many animal species [18,23-25]. However,
despite a daily circadian rhythm being demonstrated in
uterine artery blood flow [26], seasonal breeding does
not apply to primates [27], raising questions as to what
other roles it may serve in humans.
Actions as an oxygen scavenger
Free oxygen radicals are created when oxygen is utilised in
metabolic processes. These radicals contain ‘free’ valence
electrons, making them highly reactive, capable of causing
injury to cells [28]. The term ‘reactive oxygen species’
(ROS), not only includes free radicals but also stable non-
radical molecules which are capable of causing oxidation,
such as hydrogen peroxide (H2O2) [29]. While ROS are
necessary for essential physiological processes, an over-
abundance can result in cellular damage, commonly re-
ferred to as ‘oxidative stress’ [30]. Anti-oxidative agents
(oxygen-scavengers) are present endogenously but can
also be administered exogenously. They reduce free radi-
cals by donating electrons to stabilise them [31].
Recently, it has been discovered that melatonin has im-
portant oxygen-scavenging properties [32-34]. Compared
with other oxygen scavengers, melatonin is of particular
interest because it has several qualities distinguishing and
rendering it superior to classical anti-oxidative agents. For
example, it has anti-oxidative effects through its receptors,
MT1 and MT2 [35], but also as a direct free radical
scavenger [36,37]. It has binding sites within the nucleus
[13,38], and is amphiphilic, allowing it to cross cell mem-
branes freely [36,39]. But one of its most unique
characteristics is that, unlike classical anti-oxidants,
melatonin is a suicidal terminal anti-oxidant. It does
not promote oxidation under any circumstances and its
metabolites are also capable of acting as anti-oxidants
in a ‘scavenging cascade reaction’ without themselves
becoming oxidative [37,40-42]. Importantly, melatonin
also enhances the activity of other endogenous anti-
oxidants including glutathione peroxidase and super-
oxide dismutase (Figure 1) [43-47].
These unique characteristics have made melatonin the
subject of investigation into medical conditions in which
oxidative stress has been implicated, including diabetes,
glaucoma, irritable bowel syndrome and even in curtail-
ing the side effects of chemo- and radiotherapy [48,49].
Melatonin has been shown to suppress tumour growthfactors and angiogenesis, suggesting a possible role for
melatonin in prevention of cancer growth [9,50,51]. Fur-
thermore, melatonin has been shown to have anti-
inflammatory and DNA stabilising actions in the lung
[6,52], skin and intestine [53-56] and can help reduce
chronic pelvic pain in women with endometriosis [57].
Importance of melatonin in reproduction
In humans, the only data on cyclical melatonin changes
comes from women undergoing ovarian stimulation.
Levels of melatonin reach a nadir in the preovulatory
phase and peak in the luteal phase (Figure 2) [58-60]. This
suggests that melatonin has variable effects dependent on
the menstrual phase.
It is also well known that shift-workers are more likely
than daytime workers to experience circadian disruption
and longer menstrual cycles, more menorrhagia and dys-
menorrhoea [61,62]. These results are corroborated by a
very large cohort study, which also found that duration
of shiftwork was modestly associated with menstrual
cycle irregularity [63]. A Japanese study found that mela-
tonin levels varied significantly between night and day
shift workers, while LH and FSH levels did not, suggest-
ing that the menstrual irregularity associated with shift-
work could be explained by melatonin fluctuations [64].
These findings are in line with central effects on the
hypothalamic pituitary axis, being capable of modifying
the release of gonadotrophins and GnRH [65]. In fact, in
very high doses, when combined with progesterone, mela-
tonin has the ability to suppress ovulation in humans, pos-
sibly by interfering with LH release [66]. This may
represent an evolutionary remnant with inhibition of ovu-
lation during darker months designed to prevent the birth
of offspring when resources are less abundant.
Interestingly, melatonin receptors have been found on
granulosa cells, indicating that this may be an additional
site of melatonin activity [65,67,68]. Indeed, when given
systemically in cats, melatonin appears to accumulate
preferentially in the ovaries compared with other organs
[69] and higher concentrations of melatonin are found
in preovulatory follicular fluid than in serum [36,70,71].
A human study by Nakamura et al. [72] found that lar-
ger preovulatory follicles had higher concentrations of
follicular fluid melatonin than smaller immature follicles.
This is the only study that has addressed follicular fluid
differences within the same patient, and indicates that
follicular fluid from mature follicles have higher anti-
oxidant capacity than smaller follicles, implying a role
for melatonin in oocyte maturation. However, it is as yet
unclear whether this is a cause or consequence.
Adding further credence to the role of melatonin in
reproduction, melatonin requirements appear to increase
during pregnancy [73], and researchers have begun to as-
sess its role as a potential therapy in pre-eclampsia and
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tions have shown that in ovine models, intrauterine infu-
sion of melatonin results in an increase in umbilical artery
blood flow and higher fetal-placental weight ratio. Import-
antly, intrauterine infusion of a melatonin receptor antag-
onist decreased fetal aortic blood flow relative to fetal
weight, suggesting that activation of melatonin receptors
may be the mechanism behind the apparent increase in
fetal blood flow after oral melatonin supplementation [76].Figure 1 Actions of melatonin and its metabolites. Extrapolated from H
peroxidase; SOD: superoxide dismutase; ROS: Reactive oxygen species; RNSMelatonin has also been shown to reduce the neurological
effects of oxidative stress-induced fetal brain injury in rats
and sheep [77,78]. These findings support a beneficial role
of melatonin in the treatment and/or prevention of pla-
cental dysfunction, which may even extend to the treat-
ment of pre-eclampsia and neurological damage in
preterm and growth restricted neonates [4,78].
Because melatonin levels naturally decrease with age
[79,80], some investigators have found that supplementationardeland [46], Reiter et al. [13] and Watson [47]. GPx: glutathione
: Reactive nitrogen species.
Figure 2 Relative concentrations of plasma melatonin, LH, estradiol and progesterone in hMG/hCG treated cycles. Adapted with permission
from Tang et al. [59]. LH: Luteinising hormone.
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appears to have a role in the prevention of postmenopausal
bone loss, with effects being exerted via inhibition of oxida-
tive stress, induction of osteoblastogenesis and inhibition of
osteoclastogenesis [82]. These findings and evidence from a
small randomised controlled trial suggests that melatonin
may be useful in the treatment of perimenopausal and
menopausal symptoms and sequelae [83,84].
The positive implications of higher melatonin levels
on the human menstrual cycle, fertility and pregnancy
are therefore well documented, with varying levels of
evidence [32-34,85]. Nevertheless, it appears clear that
melatonin serves a purpose in the human reproductive
system, with many of its observed effects likely to be re-
lated to its ability to dampen the effects of oxidative
stress on the reproductive system.
Safety
Given the potential clinical benefits of melatonin it is
equally important to assess its potential for harm, particu-
larly when considering treatment in infertile or pregnant
populations. It is reassuring that melatonin has a remark-
ably benign safety profile in both animal and human
studies, with no teratogenic effects [86-88]. Furthermore,
melatonin does not have significant sedative effects and is
not associated with hepato-nephrotoxicity [89] even at
supraphysiological doses (5 - 20 mg/day) for prolonged
periods of administration (up to 12 weeks) in both adults
and children [66,90-92]. While non-toxic, it has been sug-
gested that melatonin can adversely affect autoimmune
conditions, particularly rheumatoid arthritis [93], through
its immuno-stimulatory actions. There have also been two
case-reports of melatonin being associated with auto-
immune hepatitis [94,95], and a suggestion that it may be
implicated in multiple sclerosis through T-cell activation
[96]. Though these effects are associative and follow bio-
logical plausibility, causality has not yet been proven [97].
Despite this, it is recommended to avoid the use of mela-
tonin in those with autoimmune conditions.
Infertility treatment
The importance of oxidative stress in assisted
reproductive technology (ART)
The relevance of oxidative stress in ART has gained in-
creasing attention in recent literature, in particular with
regards to IVF. IVF can result in exposure of oocytes
and embryos to high levels of superoxide free radicals,
which begins prior to oocyte retrieval [98]. Ovarian
stimulation protocols are associated with significant
changes to the in-vivo follicular environment, altering
endogenous levels of oxygen scavengers [99]. Further-
more, in-vitro, these oocytes are no longer protected by
antioxidant-rich follicular fluid, leaving them more sus-
ceptible to oxidative damage [100-102]. They may alsobe exposed to high oxygen concentrations in incubators
and during handling throughout the IVF process, with
higher concentrations of oxygen being associated with
more ROS, and a positive effect of melatonin being more
marked in oocytes exposed to higher oxygen tensions
[103]. This oxidative stress modifies the quality of oo-
cytes and embryos, decreasing the fertilisation rate and
the success of the infertility treatment [104-106].
Investigators have found an inverse relationship be-
tween follicular fluid levels of ROS and success of ART,
and these differences do not seem to be related to the
cause of infertility. Bedaiwy et al. sequentially analysed
the follicular fluid from 138 patients undergoing intra-
cytoplasmic sperm injection ICSI [107]. They found that
cycles that resulted in pregnancy were associated with a
significantly higher total antioxidant capacity (a measure
of the summative effect of antioxidants in the serum
[108]) and significantly lower level of ROS [107] but the
sample sizes were relatively small. This evidence sug-
gests that intra-follicular oxidative stress may have a sig-
nificant impact on IVF success rates.
While reactive oxygen species are required for sperm
capacitation events [109,110], an imbalance of ROS has
been implicated as a factor in reducing the quality and
function of sperm [111], with most protection from
these effects being afforded by the enzymatic antioxi-
dant, superoxide dismutase [112-116].
One reason for the increased susceptibility of sperm to
oxidative stress is the abundance of oxidative targets
such as polyunsaturated fatty acids in the plasma mem-
brane of sperm required for fusion with the oocyte and
fertilisation [117]. Furthermore, it has been found that
DNA fragmentation resulting from both in-vivo and in-
vitro oxidative stress is a major contributor to poor
sperm quality and function, and that antioxidative ther-
apies may hold promise in attenuating these effects
[118]. As might be expected, such DNA damage has
been shown to have a negative impact on fertilisation,
blastocyst development [119], and miscarriage rates and
pregnancy outcome [120].
The recognition of the association between exposure
of gametes and embryos to oxidative stress and a reduc-
tion in the success rates of IVF has led investigators to
assess whether these adverse effects can either be pre-
vented or reversed, with emphasis being placed on the
adjuvant use of oxygen scavengers including melatonin.
The role of melatonin in assisted reproductive technology
Oxidative stress occurs at many levels during the treat-
ment of infertility. Interventional studies have begun re-
cently, with an emphasis on oral supplementation of
melatonin during the ovarian stimulation phase of the
IVF cycle and its effects on gamete and embryo quality.
Clinical studies assessing the use of melatonin in IVF are
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Effects of melatonin on oocyte quality
Melatonin is an effective mitigator of mitochondrial
DNA damage [121], likely as a result of an increase in
electron transport efficiency within mitochondria, thus
preventing the formation of ROS [122]. In some situations
melatonin may be even more effective at performing this
function than specific mitochondrial antioxidants [123],
and this particular characteristic may have relevance to its
use in the treatment of infertility and the improvement of
oocyte quality and maturity.
Oocyte quality begins to deteriorate immediately fol-
lowing ovulation, a process thought to be inflammatory
[124] and through its production of cytokines and prote-
ases is associated with an increase in ROS which can in-
hibit oocyte maturation [13,125,126]. A very recent
murine study found that oxidative stress in oocytes may
begin as early as 8 hours after ovulation, rising exponen-
tially thereafter. This study also found that in-vitro
addition of 1 mM of melatonin to oocyte culture media
significantly ameliorated these time-dependent effects,
resulting in 54% of fertilise oocytes reaching the blasto-
cyst stage in the presence of melatonin compared with
29% in the controls [127]. This study not only showed
that an imbalance of ROS is an important cause of im-
paired oocyte quality in-vitro, but also that the addition
of melatonin could reverse these effects.
The follicular environment is naturally protective
against oxidative damage to the oocyte [128]. To illus-
trate this, Tamura et al. sampled follicular fluid at oocyte
retrieval and measured intrafollicular concentrations of
melatonin and the oxidative stress marker, 8-hydroxy-
2′-deoxyguanosine (8-OHdG). Melatonin concentrations
were directly proportional to follicular growth and, as
expected, inversely correlated with 8-OHdG levels.
Kang et al. [129] investigated in-vitro porcine oocyte
media supplemented with and without melatonin. They
found a significantly lower level of ROS and a greater
proportion of MII (mature) oocytes in the melatonin
group but without an increase in cleavage frequency or
blastocyst cell number. Tamura et al. [125] incubated
mouse germinal vesicles exposed to H2O2 with several
different concentrations of melatonin. After 12 hours, a
positive dose–response relationship was found between
increasing amounts of melatonin and the number of ma-
ture oocytes. These results strongly suggest that melatonin
supplementation in-vitro is associated with a reduction in
oxidative stress and improved oocyte maturation.
The literature is conflicting, however, with other ani-
mal studies finding an optimal melatonin range of 10−6
to 10−9 M in in-vitro maturation media, with both
higher and lower doses having negative effects [130,131].These findings are in agreement with human studies
which have demonstrated that lower concentrations of
melatonin in culture media improved nuclear matur-
ation rate of immature MI oocytes [132], implantation
rate and an insignificant increase in clinical pregnancy rate
[133] with an optimal threshold of 10−5 M to 10−9 M. Both
studies agreed that higher concentrations worsened out-
comes. Although there is significant evidence to support a
role for melatonin in oocyte maturation in-vitro, further
investigation is warranted to confirm the optimal effective
dose.
A recent review concluded that oral administration of
melatonin reduces intrafollicular oxidative damage and
increases fertilisation rates [36]. Unfortunately, most
studies addressing the use of melatonin in infertility treat-
ment have been conducted with patients as their own con-
trols (‘before and after’ comparison) [36,125,134]. In the
absence of proper control or placebo groups, it must be
assumed that any beneficial effects thus observed are ex-
plained by the phenomenon of regression toward the
mean [135,136].
Other human studies have been promising, but unfor-
tunately, have also been challenged by design limitations.
Eryilmaz et al. [137] performed an unblinded randomise
controlled trial assessing melatonin supplementation in
women with sleep disturbances undergoing IVF. The in-
vestigators randomise 30 patients to receive 3 mg nocte
of oral melatonin from day 3–5 of their cycle up until
administration of the human chorionic gonadotrophin
(HCG) trigger. Controls received no additional treat-
ment. They found a significantly increased number of
oocytes, increased number of metaphase II oocytes and
increased percentage of Grade 1 embryos (69.3% vs
44.8%, p < 0.05). The authors did not mention control-
ling or accounting for concurrent adjuvant treatments,
nor did they account for the number of previous failed
IVF cycles. In addition, their patients had a mean dur-
ation of infertility of 6–7 years and the aetiology of infer-
tility was not considered.
Despite its limitations, these findings were in keeping
with another larger unblinded randomised trial looking
specifically at the effect of melatonin on IVF outcomes.
Eighty women were randomised to receiving melatonin
3 mg/day or no treatment from the commencement of
GnRH agonist administration. The percentage of mature
oocytes was higher in the melatonin group (p < 0.05) as
was the proportion of high quality embryos, however, an
increase in clinical pregnancy rate did not reach statis-
tical significance [138]. Additionally, patients with can-
celled cycles were not included in the analysis making
these findings susceptible to attrition bias.
One drawback of the studies already discussed is the
lack of a placebo control. Others have overcome the
challenge of recruiting patients for a placebo-controlled
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2+ 115 3 mg melatonin po from
day 5 to oocyte
collection (n = 56)








2− 112 3 mg melatonin po from
day 5 to oocyte
collection (n = 56)
Previous cycle without
melatonin (n = 56)
Higher fertilisation rate in melatonin cycle
(50% vs 20.2%)*







1− 60 3 mg melatonin po from
day 3–5 until HCG
injection (n = 30)
No melatonin (n = 30) Higher number of oocytes in melatonin
group (11.5 vs 6.9)*
Higher MII oocyte counts (9 vs 4.4)*
Higher G1 embryo transfer rate
(69.3 vs 44.8)*
No differences in fertilisation,










1− 85 3 mg melatonin po
(n = 40)
No melatonin (n = 45) Higher percentage of MII oocytes in
melatonin group (81.9% vs 75.8%)*
Higher number of G1 embryos
(3.2 vs 2.5)*
No difference in number of oocytes,







2− 97 3 mg melatonin po for at
least 2 weeks leading up
to HCG trigger in second
cycle (n = 97)
No melatonin in first cycle
(n = 97)
Higher ICSI fertilisation rate in melatonin
group (77.5% vs 69.3%)*
Higher rate of good quality embryos
(Day 3) (65.6% vs 48.0%)*
No difference in maturation rate,








1− 65 3 mg melatonin daily
+2 g myo-inositol po bd
+200mcg folic acid po
bd from day of GnRH
administration (n = 32)
2 g myo-inositol po bd
+200mcg folic acid po bd
from day of GnRH
administration (n = 33)
Higher number of MII oocytes in
melatonin group (6.56 vs 5.76)*
Lower number of immature oocytes
(1.31 in vs 1.90)*
No difference in fertilisation rate,







2− 46 2 g myo-inositol po
+200mcg folic acid po in
the morning and 3 mg
melatonin po +2 g myo-
inositol po +200mcg folic
acid po in the evening
for 3 months leading to
second cycle of IVF
No trial medication in first
cycle
Higher number of MI and MII oocytes in
treatment cycle (3.11 vs 2.35)*
Higher number of G1 or G2 embryos
transferred (0.35 vs 0.13)*
Clinical pregnancy rate 19.6% in
treatment cycle









1+ 388 3 mg melatonin po +4 g
myo-inositol po
+400mcg folic acid po
(n = 178)
4 g myo-inositol +400mcg
folic acid po (n = 180)
Higher percentage of mature oocytes in
melatonin group (48.2% vs 35.0%)*
Higher percentage of G1 embryos
(45.7% vs 30.4%)*
IVF: In-vitro fertilisation; NICE: National Institute for Health and Care Excellence; *statistically significant; G1: Grade 1; G2: Grade 2; MI: Meiosis I; MII: Meiosis II; ICSI:
Intracytoplasmic sperm injection; HCG: Human chorionic gonadotrophin; po: per oral; bd: Twice per day.
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A prospective non-placebo controlled trial comparing
myo-inositol (an insulin sensitizing agent) and folate
supplementation to myo-inositol, folate and melatonin
found that those in the melatonin group achieved a
greater number of mature oocytes, fewer immature oo-
cytes and a greater number of top-quality embryos
[139]. While this suggests an independent effect of mela-
tonin, it may be that melatonin acts synergistically with
these agents, given that melatonin can enhance the ef-
fect of other antioxidants (Figure 1). Indeed, other inves-
tigators have shown that myo-inositol may also be a
useful treatment for infertility in polycystic ovarian syn-
drome (PCOS), with improvements observed in the
quantity of mature oocytes, the number of top quality
embryos and the clinical pregnancy rates [140].
Effects of melatonin on sperm quality
It appears that the reproductive effects of melatonin do
not extend only to the female counterpart, with mela-
tonin receptors being demonstrated on spermatozoa
[141]. In general, it is accepted that a higher percentage
of motile sperm is associated with improved fertilisation
rates and Ortiz et al. has shown that the addition of
melatonin to seminal samples can improve the overall
motility and the percentage of progressively motile
spermatozoa [142,143]. Melatonin also appears to inhibit
apoptosis in spermatozoa, with a reduction in early
apoptotic events being demonstrated in human sperm
thus prolonging sperm survival [144]. These effects
would serve to improve sperm quality, therefore increas-
ing the probability of successful fertilisation.
Melatonin, through its neutralisation of reactive oxygen
and nitrogen species, has been shown in both animal and
human studies to improve seminal quality in-vitro. A
study investigating the addition of melatonin to semen ex-
tender in cryopreserved seminal samples from Holstein
bulls resulted in amelioration of the oxidative effects of
the freeze-thaw process [145]. Studies in rats also have
shown that melatonin has a positive effect on sperm that
have been subjected to oxidative stress, improving sperm
number, viability and motility [146-148]. Similar results
have been found in a small human study in which in-vitro
melatonin-treated samples showed a higher percentage of
sperm motility and a lower proportion of non-viable
spermatozoa [149]. These authors suggested that the
mechanism behind their findings was the result of mela-
tonin neutralising reactive nitrogen species [149].
Effects of melatonin on embryo culture media
Following retrieval, the micro-environment that gametes
and embryos are cultured in is an essential determinant
of subsequent fertilisation and implantation success.
Many investigators have studied the impact of melatoninsupplementation of in-vitro culture media in porcine,
murine and bovine embryo development, overall demon-
strating a beneficial effect [150-152].
Bovine studies have found a higher cleavage rate, in-
creased 8-cell embryo yield and an increased number of
blastocysts and blastocyst hatching in embryos cultured
with melatonin concentrations ranging between 10−5 and
10−11 M [153-156]. Like supplementation of oocyte cul-
ture media, it appears that higher concentrations of mela-
tonin in embryo culture media can be harmful [157].
Therefore, it appears that in-vitro supplementation of
embryo culture media with melatonin has a significant
impact on the development and quality of embryos, with
lower concentrations being more beneficial (and less
harmful) than higher ones.
Effects of melatonin on luteal function
Progesterone is an essential hormone in the develop-
ment of a receptive endometrium and for support of
early pregnancy, and without it, pregnancy will fail. In a
normal menstrual cycle, this progesterone is provided by
the corpus luteum, which develops when the granulosa
cells in the ruptured follicle luteinise. A certain level of
ROS are required for normal ovulation (follicular rup-
ture) and corpus luteal function. An imbalance of ROS
results in oxidative stress and this has been identified as
a potential cause of luteal phase defect [158,159].
Studies have also sought to identify the role of mela-
tonin administration during the luteal phase in patients
undergoing IVF. A prospective study of 25 women with
luteal phase defect compared 14 women who were given
3 mg/d of melatonin from the time of their HCG trigger
throughout the luteal phase with 11 women who were
given no supplements. The findings showed that mela-
tonin supplementation significantly increased progester-
one levels (11.0 ng/ml vs 8.9 ng/ml, p < 0.05) [160].
Another study found that melatonin can increase serum
progesterone levels in women with a luteal phase defect,
but this study did not have a control arm and the ob-
served differences in serum concentrations (<10 ng/ml)
were not clinically significant, making the relevance of
these findings questionable [161]. Consequently, the ap-
plication of melatonin for luteal phase support is yet to
be confirmed.
Effects of melatonin on pregnancy rates - human studies
Several trials designed to determine the efficacy of mela-
tonin in improving pregnancy rates have considered it in
combination with folic acid and myo-inositol, a B com-
plex vitamin synthesized endogenously from glucose
[139,162-164].
Rizzo et al. [139] in a prospective trial of 65 women
compared myo-inositol and folate supplementation to
myo-inositol, folate and melatonin. They found a trend
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tonin group, but this did not reach statistical
significance.
In a larger double blind randomised controlled trial
addressing these agents in PCOS patients undergoing
ICSI, Pacchiarotti et al. [164] allocated 178 patients to
triple therapy (myo-inositol 4 g, folic acid 400mcg and
melatonin 3 mg per day) and 180 patients to myo-
inositol and folic acid alone [164]. With this larger sam-
ple size, they found higher numbers of mature oocytes
(48% vs 35%, p = 0.008) and grade 1 embryos (45.7% vs
30.4%, p = 0.0045) in patients treated with triple therapy,
supporting the role of melatonin in the treatment of in-
fertility caused by PCOS. This does not necessarily dem-
onstrate an independent effect of melatonin on embryo
quality or oocyte maturity, and as discussed previously,
may represent a synergistic effect with myo-inositol and
folic acid, although this has not been proven.
Overall, only a limited number of clinical studies have
investigated the use of melatonin to improve pregnancy
outcomes in infertile women. These studies have gener-
ally been poorly designed, have often compared combin-
ation regimens, have investigated a narrow range of
melatonin doses and have been unable to conclusively
identify an independent positive role for melatonin on
clinical pregnancy rates after IVF. There clearly is a need
for a large randomised double blind placebo-controlled
trial to investigate whether oral melatonin increases clin-
ical pregnancy rates in IVF patients and which dose pro-
vides maximal benefit.
Tamura et al. [125] investigated the role of melatonin
supplementation in 115 patients who failed to become
pregnant in a previous cycle of IVF/ET, with a fertilisation
rate of less than or equal to 50%. They used a dose of
3 mg/day in the next IVF cycle from day 5 of the men-
strual cycle until oocyte retrieval. The fertilisation rate was
significantly higher in the melatonin group when com-
pared with their first cycle (50.0 ± 38.0% vs 22.8 ± 19.0%,
p < 0.01). In addition, intrafollicular melatonin concen-
trations were significantly increased and the oxidative
stress marker 8-OHdG was significantly decreased by
melatonin treatment [125]. Furthermore, the pregnancy
rate trended towards an improvement in the melatonin
group, albeit not reaching statistical significance.
Another prospective longitudinal cohort study ad-
dressed the effects on myo-inositol and melatonin sup-
plementation in women who failed to conceive in
previous IVF cycles because of poor oocyte quality [165].
Forty six women were treated with myo-inositol 4 g/day
and melatonin 3 mg/day for three months and then
underwent another IVF cycle. After this treatment, there
were statistically significant improvements in the
number of mature oocytes and fertilisation rate. The
number of top-quality embryos transferred was alsohigher than the previous cycle. The clinical pregnancy
rate after supplementation was 19.6%. Because this was
a before-after study and patients were only included if
they failed to conceive in their first cycle, it is difficult to
comment on the significance of this clinical pregnancy
rate as an appropriate control group was not used.
Unfortunately, both studies were of low quality using a
before and after comparison with regression to the mean
likely explaining observed differences [136].
Systematic reviews and meta-analyses
Only one meta-analysis has been performed specifically
assessing the use of melatonin in IVF. This recent sys-
tematic review and meta-analysis of five randomise con-
trolled trials found a pooled risk ratio of 1.21 (95% CI
0.98 - 1.50) in favour of melatonin for the outcome of
clinical pregnancy rate. However, the authors suggested
that the adequacy of the data evaluating the usefulness
of melatonin is poor, and that it should not yet be rec-
ommended for routine use [166]. While they did not
find any worsening of the outcomes of IVF, the authors
commented on the lack of live birth rate as an outcome
measure as well as the imprecision encountered in all
studies considered [166].
On the other hand, melatonin is also known to be re-
markably safe, with the Cochrane systematic review and
meta-analysis finding no association between antioxidant
supplementation and adverse effects for women involved
in treatment [88]. This meta-analysis which considered
studies of melatonin as well as other antioxidants, found
a similar non-statistically significant improvement in
clinical pregnancy rate when using any antioxidant (OR
1.30, 95% CI 0.92 - 1.85) with a total sample size of over
2000 patients [88].
Conclusion and future directions
While the beneficial nature of melatonin, an endogenous
anti-oxidant, has been known for decades, the investiga-
tion into the role of melatonin in the treatment of infer-
tility is still in its infancy. Good quality evidence has
emerged from other disciplines indicating the utility of
melatonin in the treatment of a variety of medical condi-
tions. For example, a recent phase II double blind pla-
cebo controlled randomised trial has shown that
melatonin can help reduce chronic pelvic pain in women
with endometriosis potentially through its effects on
brain-derived neurotrophic factor and beneficial effects
on sleep quality [57]. Level II evidence has also deter-
mined the effectiveness of melatonin as an analgesic in
temporomandibular disorders [167] and as a method of
reducing oxidative stress and improving dyspnoea in pa-
tients with chronic obstructive pulmonary disease [6].
Despite this, melatonin use in infertility treatment still
lacks adequate evidence to recommend routine use.
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levels of reactive oxygen species which have the potential
to negatively affect the quality of oocytes and embryos.
Melatonin shows promise as an adjunctive therapy in
the treatment of infertility. Its unique anti-oxidative
characteristics and safety profile make it an ideal poten-
tial adjuvant therapy to be further investigated in well
designed double blind randomised placebo-controlled
trials.
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